AstraZeneca, Absci sign $247M agreement to uncover AI-driven cancer drug candidates
Absci, a startup focused on developing generative AI antibody discovery technology, announced a potential $247 million partnership with pharma giant AstraZeneca to focus on expediting the discovery of novel cancer treatments with the help…
Continue Reading